Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications
CA 2403442 A1 · Owner: Ajinomoto Co. Inc. · Inventors: Miura, Kyoko; Kitahara, Yoshiro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Drugs containing postcibal hypoglycemics as the active ingredient which are efficacious in preventing, ameliorating and treating complications of diabetes, neuropathy, etc. In particular D-phenylalanine derivatives such as , nateglinide are useful as oral drugs. These excellent drugs methods of using , the same (for example administration for treating the above diseases etc.), utilization of postcibal hypoglycemics in the production of these drugs etc. , are provided. The above-described effects of preventing ameliorating and , treating the complications can be further enhanced by adding at least one member selected from among hypotensive agents peripheral circulation , improving agents …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 15, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 15, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 15, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.